Core Viewpoint - Marex Group plc has been included in the Russell 3000 Index and the small-cap Russell 2000 Index, marking a significant milestone for the company as a public entity, which is expected to enhance its visibility among a wider range of investors [1][2]. Company Overview - Marex Group plc (NASDAQ: MRX) is a diversified global financial services platform that provides essential liquidity, market access, and infrastructure services across energy, commodities, and financial markets [5]. - The company offers a comprehensive range of services, including Clearing, Agency and Execution, Market Making, and Hedging and Investment Solutions, with a strong presence in major metals, energy, and agricultural products [5]. - Marex has access to 60 exchanges and serves a diverse clientele, including large commodity producers, consumers, traders, banks, hedge funds, and asset managers [5]. - The company operates more than 40 offices globally and employs over 2,400 staff across Europe, Asia, and the Americas [5]. Market Context - The Russell indexes are widely utilized by investment managers and institutional investors for index funds and as benchmarks for active investment strategies, with approximately $10.6 trillion in assets benchmarked against these indexes as of June 2024 [2].

Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges [5] - The company is advancing TNX-102 SL, a product candidate for the management of fibromyalgia, with a PDUFA goal date of August 15, 2025, for marketing authorization [5] - Tonix's development portfolio includes biologics for organ transplant rejection, autoimmunity, and cancer, as well as vaccines for infectious diseases [5] Market Position - Tonix Pharmaceuticals will be added to the Russell 3000® Index and automatically included in the small-cap Russell 2000® Index as part of the 2025 Russell indexes reconstitution [1][3] - The Russell indexes are widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against them as of June 2024 [3] Strategic Goals - The inclusion in the Russell Indexes is expected to enhance the company's visibility and awareness as it progresses towards potential FDA approval for TNX-102 SL [3] - The company is also developing TNX-4200, a broad-spectrum antiviral agent, under a contract with the U.S. Department of Defense for up to $34 million over five years [5]

Core Points - Xenon Pharmaceuticals Inc. has been added to the Russell 3000® and Russell 2000® Indexes as part of the annual reconstitution effective June 27, 2025 [1] - The Russell 3000® Index tracks the performance of the largest 3,000 U.S. stocks by market capitalization, while the Russell 2000® Index measures the performance of the 2,000 smallest companies within the Russell 3000® Index [2] - Approximately $10.6 trillion in assets are benchmarked against Russell U.S. indexes, making them widely used by investment managers and institutional investors [3] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics [4] - The company is advancing an ion channel product portfolio to address high unmet medical needs, including epilepsy and depression [4] - Azetukalner, a novel and highly potent selective Kv7 potassium channel opener, is the most advanced clinically validated potassium channel modulator in late-stage clinical development for multiple indications [4]

Group 1 - aTyr Pharma, Inc. is expected to be added to the Russell 2000 Index and the Russell 3000 Index effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution [1] - The Russell 3000 Index tracks the performance of the largest 3,000 publicly traded U.S. companies, while the Russell 2000 Index focuses on small-cap companies [2] - Membership in the Russell Indexes lasts for one year and results in automatic inclusion in appropriate growth and value style indexes, which are utilized by investment managers and institutional managers [2] Group 2 - aTyr is a clinical stage biotechnology company that focuses on developing first-in-class medicines from its proprietary tRNA synthetase platform [4] - The company's lead therapeutic candidate is efzofitimod, which is in clinical development for treating interstitial lung disease, a group of immune-mediated disorders [4]